BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38:954-962. [PMID: 25998286 DOI: 10.2337/dc15-0184] [Cited by in Crossref: 130] [Cited by in F6Publishing: 102] [Article Influence: 18.6] [Reference Citation Analysis]
Number Citing Articles
1 Penno G, Russo E, Garofolo M, Daniele G, Lucchesi D, Giusti L, Sancho Bornez V, Bianchi C, Dardano A, Miccoli R, Del Prato S. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia 2017;60:1102-13. [PMID: 28357502 DOI: 10.1007/s00125-017-4251-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
2 Bartáková V, Klimešová L, Kianičková K, Dvořáková V, Malúšková D, Řehořová J, Svojanovský J, Olšovský J, Bělobrádková J, Kaňková K. Resting Heart Rate Does Not Predict Cardiovascular and Renal Outcomes in Type 2 Diabetic Patients. J Diabetes Res 2016;2016:6726492. [PMID: 26824046 DOI: 10.1155/2016/6726492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Furuichi K, Shimizu M, Yuzawa Y, Hara A, Toyama T, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ubara Y, Hohino J, Hisano S, Ueda Y, Nishi S, Yokoyama H, Nishino T, Kohagura K, Ogawa D, Mise K, Shibagaki Y, Makino H, Matsuo S, Wada T; Research Group of Diabetic Nephropathy, Ministry of Health, Labour and Welfare of Japan, and Japan Agency for Medical Research and Development. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin Exp Nephrol 2018;22:570-82. [PMID: 29080120 DOI: 10.1007/s10157-017-1485-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
4 Nabity MB, Polli JW, Vaidya V, Krolewski A, Glaab WE. New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity. Toxicol Pathol 2018;46:1002-5. [PMID: 30189777 DOI: 10.1177/0192623318798599] [Reference Citation Analysis]
5 Griffin TP, O'shea PM, Smyth A, Islam MN, Wall D, Ferguson J, O'sullivan E, Finucane FM, Dinneen SF, Dunne FP, Lappin DW, Reddan DN, Bell M, O'brien T, Griffin DG, Griffin MD. Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe. BMJ Open Diab Res Care 2021;9:e002125. [DOI: 10.1136/bmjdrc-2021-002125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Misra PS, Szeto SG, Krizova A, Gilbert RE, Yuen DA. Renal histology in diabetic nephropathy predicts progression to end-stage kidney disease but not the rate of renal function decline. BMC Nephrol 2020;21:285. [PMID: 32682403 DOI: 10.1186/s12882-020-01943-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 MacIsaac RJ, Farag M, Obeyesekere V, Clarke M, Boston R, Ward GM, Jerums G, Ekinci EI. Changes in soluble tumor necrosis factor receptor type 1 levels and early renal function decline in patients with diabetes. J Diabetes Investig 2019;10:1537-42. [PMID: 30989829 DOI: 10.1111/jdi.13061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Yoshibayashi M, Kume S, Yasuda-Yamahara M, Yamahara K, Takeda N, Osawa N, Chin-Kanasaki M, Nakae Y, Yokoi H, Mukoyama M, Asanuma K, Maegawa H, Araki SI. Protective role of podocyte autophagy against glomerular endothelial dysfunction in diabetes. Biochem Biophys Res Commun 2020;525:319-25. [PMID: 32089264 DOI: 10.1016/j.bbrc.2020.02.088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Hering BJ, O'Connell PJ. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 6: patient selection for pilot clinical trials of islet xenotransplantation. Xenotransplantation 2016;23:60-76. [PMID: 26918540 DOI: 10.1111/xen.12228] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
10 Eckel RH, Bornfeldt KE, Goldberg IJ. Cardiovascular disease in diabetes, beyond glucose. Cell Metab 2021;33:1519-45. [PMID: 34289375 DOI: 10.1016/j.cmet.2021.07.001] [Reference Citation Analysis]
11 Nowak N, Skupien J, Smiles AM, Yamanouchi M, Niewczas MA, Galecki AT, Duffin KL, Breyer MD, Pullen N, Bonventre JV, Krolewski AS. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int 2018;93:1198-206. [PMID: 29398132 DOI: 10.1016/j.kint.2017.11.024] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
12 Colhoun HM, Marcovecchio ML. Biomarkers of diabetic kidney disease. Diabetologia 2018;61:996-1011. [PMID: 29520581 DOI: 10.1007/s00125-018-4567-5] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
13 Banerjee D, Winocour P, Chowdhury TA, De P, Wahba M, Montero R, Fogarty D, Frankel AH, Karalliedde J, Mark PB, Patel DC, Pokrajac A, Sharif A, Zac-Varghese S, Bain S, Dasgupta I; Association of British Clinical Diabetologists and The Renal Association. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol 2022;23:9. [PMID: 34979961 DOI: 10.1186/s12882-021-02587-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Xu R, Cai H, Fan Z, Wan Y, Gao X. The change in kidney function was associated with carotid artery plaque in a community-based population: A cohort study. Nutr Metab Cardiovasc Dis 2021;31:119-26. [PMID: 32994120 DOI: 10.1016/j.numecd.2020.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Samuelsson M, Dereke J, Svensson MK, Landin-Olsson M, Hillman M; on the behalf of the DISS Study group. Soluble plasma proteins ST2 and CD163 as early biomarkers of nephropathy in Swedish patients with diabetes, 15-34 years of age: a prospective cohort study. Diabetol Metab Syndr 2017;9:41. [PMID: 28559931 DOI: 10.1186/s13098-017-0240-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
16 Niewczas MA, Mathew AV, Croall S, Byun J, Major M, Sabisetti VS, Smiles A, Bonventre JV, Pennathur S, Krolewski AS. Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. Diabetes Care 2017;40:383-90. [PMID: 28087576 DOI: 10.2337/dc16-0173] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 12.6] [Reference Citation Analysis]
17 Darenskaya MA, Chugunova EV, Kolesnikov SI, Grebenkina LA, Semenova NV, Nikitina OA, Kolesnikova LI. Content of Carbonyl Compounds and Parameters of Glutathione Metabolism in Men with Type 1 Diabetes Mellitus at Preclinical Stages of Diabetic Nephropathy. Bull Exp Biol Med 2021;171:592-5. [PMID: 34617170 DOI: 10.1007/s10517-021-05275-4] [Reference Citation Analysis]
18 Seo DH, Kim SH, Nam M. Response: Presence of Carotid Plaque Is Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Normal Renal Function (Diabetes Metab J 2019;43:840-53). Diabetes Metab J 2020;44:205-6. [PMID: 32098003 DOI: 10.4093/dmj.2020.0025] [Reference Citation Analysis]
19 Shestakova MV. [Diabetes mellitus and chronic kidney disease: Possibilities of prediction, early diagnosis, and nephroprotection in the 21st century]. Ter Arkh 2016;88:84-8. [PMID: 27489899 DOI: 10.17116/terarkh201688684-88] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Pop-Busui R, Ang L, Holmes C, Gallagher K, Feldman EL. Inflammation as a Therapeutic Target for Diabetic Neuropathies. Curr Diab Rep 2016;16:29. [PMID: 26897744 DOI: 10.1007/s11892-016-0727-5] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 15.7] [Reference Citation Analysis]
21 Yang Y, Huang H, Xu Z, Duan JK. Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease. J Diabetes Res 2017;2017:7680576. [PMID: 28929122 DOI: 10.1155/2017/7680576] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
22 Dąbrowski M, Mielnik-Niedzielska G, Nowakowski A. Association between hearing organ and renal function in young adult type 1 diabetic patients: A cross-sectional study. Sci Rep 2018;8:12645. [PMID: 30140038 DOI: 10.1038/s41598-018-31057-6] [Reference Citation Analysis]
23 Oshima M, Toyama T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, Araki S, Ninomiya T, Hara S, Suzuki Y, Iwano M, Kusano E, Moriya T, Satoh H, Nakamura H, Shimizu M, Hara A, Makino H, Wada T; Research Group of Diabetic Nephropathy, Ministry of Health, Labour, and Welfare of Japan. Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. PLoS One 2018;13:e0201535. [PMID: 30071057 DOI: 10.1371/journal.pone.0201535] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
24 Bae J, Won YJ, Lee BW. Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD). Life (Basel) 2021;11:224. [PMID: 33802211 DOI: 10.3390/life11030224] [Reference Citation Analysis]
25 An L, Yu Q, Tang H, Li X, Wang D, Tang Q, Xing H, He Y, Zhao X, Zhao S, Lee Y, Lu J. The Prevalence, Progress and Risk Factor Control of Chronic Kidney Disease in Chinese Adults With Type 2 Diabetes Mellitus in Primary Care. Front Endocrinol (Lausanne) 2022;13:859266. [PMID: 35757423 DOI: 10.3389/fendo.2022.859266] [Reference Citation Analysis]
26 Xu JZ, Garrett ME, Soldano KL, Chen ST, Clish CB, Ashley-Koch AE, Telen MJ. Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. Am J Hematol 2018;93:1451-60. [PMID: 30144150 DOI: 10.1002/ajh.25263] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
27 Furuichi K, Shimizu M, Hara A, Toyama T, Wada T. Diabetic Nephropathy: A Comparison of the Clinical and Pathological Features between the CKD Risk Classification and the Classification of Diabetic Nephropathy 2014 in Japan. Intern Med 2018;57:3345-50. [PMID: 30101924 DOI: 10.2169/internalmedicine.1132-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
28 Penno G, Russo E, Garofolo M, Daniele G, Lucchesi D, Giusti L, Sancho Bornez V, Bianchi C, Dardano A, Miccoli R, Del Prato S. Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter]. Diabetologia 2017;60:2123-5. [PMID: 28770329 DOI: 10.1007/s00125-017-4387-z] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Pacilli A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S; AMD-Annals Study Group. Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative. Diabetes Metab Res Rev 2017;33. [PMID: 27935651 DOI: 10.1002/dmrr.2873] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
30 Nowak N, Skupien J, Niewczas MA, Yamanouchi M, Major M, Croall S, Smiles A, Warram JH, Bonventre JV, Krolewski AS. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int 2016;89:459-67. [PMID: 26509588 DOI: 10.1038/ki.2015.314] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 10.8] [Reference Citation Analysis]
31 Hongbo M, Yanjiao D, Shuo W, Kun S, Yanjie L, Mengmeng L. Podocyte RNF166 deficiency alleviates diabetic nephropathy by mitigating mitochondria impairment and apoptosis via regulation of CYLD signal. Biochem Biophys Res Commun 2021;545:46-53. [PMID: 33545631 DOI: 10.1016/j.bbrc.2020.12.014] [Reference Citation Analysis]
32 Rodriguez-Romero V, Bergstrom RF, Decker BS, Lahu G, Vakilynejad M, Bies RR. Prediction of Nephropathy in Type 2 Diabetes: An Analysis of the ACCORD Trial Applying Machine Learning Techniques. Clin Transl Sci 2019;12:519-28. [PMID: 31112000 DOI: 10.1111/cts.12647] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
33 Mirijello A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Russo GT, Guida P, Pontremoli R, De Cosmo S; AMD ANNALS Study Group. Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. BMC Nephrol 2018;19:347. [PMID: 30514308 DOI: 10.1186/s12882-018-1136-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Zhou Z, Liu XQ, Zhang SQ, Qi XM, Zhang Q, Yard B, Wu YG. Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients. Amino Acids 2021;53:687-700. [PMID: 33811534 DOI: 10.1007/s00726-021-02975-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Mende C. Management of Chronic Kidney Disease: The Relationship Between Serum Uric Acid and Development of Nephropathy. Adv Ther 2015;32:1177-91. [PMID: 26650815 DOI: 10.1007/s12325-015-0272-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
36 Colombo M, McGurnaghan SJ, Blackbourn LAK, Dalton RN, Dunger D, Bell S, Petrie JR, Green F, MacRury S, McKnight JA, Chalmers J, Collier A, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network (SDRN) Type 1 Bioresource Investigators. Comparison of serum and urinary biomarker panels with albumin/creatinine ratio in the prediction of renal function decline in type 1 diabetes. Diabetologia 2020;63:788-98. [PMID: 31915892 DOI: 10.1007/s00125-019-05081-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
37 MacIsaac RJ, Jerums G, Ekinci EI. Glycemic Control as Primary Prevention for Diabetic Kidney Disease. Adv Chronic Kidney Dis 2018;25:141-8. [PMID: 29580578 DOI: 10.1053/j.ackd.2017.11.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Ihara K, Skupien J, Krolewski B, Md Dom ZI, O'Neil K, Satake E, Kobayashi H, Rashidi NM, Niewczas MA, Krolewski AS. A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. Kidney Int 2021;99:725-36. [PMID: 32717193 DOI: 10.1016/j.kint.2020.07.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
39 Furuichi K, Shimizu M, Okada H, Narita I, Wada T. Clinico-pathological features of kidney disease in diabetic cases. Clin Exp Nephrol 2018;22:1046-51. [PMID: 29564666 DOI: 10.1007/s10157-018-1556-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Piscitelli P, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S. Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Sci Rep 2017;7:3313. [PMID: 28607417 DOI: 10.1038/s41598-017-03551-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
41 Seo DH, Kim SH, Song JH, Hong S, Suh YJ, Ahn SH, Woo JT, Baik SH, Park Y, Lee KW, Kim YS, Nam M; KNDP Study Group. Presence of Carotid Plaque Is Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Normal Renal Function. Diabetes Metab J 2019;43:840-53. [PMID: 30877715 DOI: 10.4093/dmj.2018.0186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
42 Yu L, Wang Y, Guo YH, Wang L, Yang Z, Zhai ZH, Tang L. HIF-1α Alleviates High-Glucose-Induced Renal Tubular Cell Injury by Promoting Parkin/PINK1-Mediated Mitophagy. Front Med (Lausanne) 2021;8:803874. [PMID: 35186974 DOI: 10.3389/fmed.2021.803874] [Reference Citation Analysis]
43 Jiang G, Luk AOY, Tam CHT, Xie F, Carstensen B, Lau ESH, Lim CKP, Lee HM, Ng ACW, Ng MCY, Ozaki R, Kong APS, Chow CC, Yang X, Lan HY, Tsui SKW, Fan X, Szeto CC, So WY, Chan JCN, Ma RCW; Hong Kong Diabetes Register TRS Study Group. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes. Kidney Int 2019;95:178-87. [PMID: 30415941 DOI: 10.1016/j.kint.2018.08.026] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
44 Gao B, Wu S, Wang J, Yang C, Chen S, Hou J, Li J, Yang Y, He K, Zhao M, Chen M, Zhang L. Clinical features and long-term outcomes of diabetic kidney disease - A prospective cohort study from China. J Diabetes Complications 2019;33:39-45. [PMID: 30482493 DOI: 10.1016/j.jdiacomp.2018.09.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
45 Hashemi E, Dehghanbanadaki H, Baharanchi AA, Forouzanfar K, Kakaei A, Mohammadi SM, Zeidi S, Razi F. WT1 and ACE mRNAs of blood extracellular vesicle as biomarkers of diabetic nephropathy. J Transl Med 2021;19:299. [PMID: 34246281 DOI: 10.1186/s12967-021-02964-6] [Reference Citation Analysis]
46 Md Dom ZI, Satake E, Skupien J, Krolewski B, O'Neil K, Willency JA, Dillon ST, Wilson JM, Kobayashi H, Ihara K, Libermann TA, Pragnell M, Duffin KL, Krolewski AS. Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. Sci Transl Med 2021;13:eabd2699. [PMID: 34193611 DOI: 10.1126/scitranslmed.abd2699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Nonomura K, Iizuka K, Kuwabara-Ohmura Y, Yabe D. SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes. Intern Med 2020;59:1535-9. [PMID: 32188813 DOI: 10.2169/internalmedicine.4323-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Liang X, Wang P, Chen B, Ge Y, Gong AY, Flickinger B, Malhotra DK, Wang LJ, Dworkin LD, Liu Z, Gong R. Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease. Kidney Int 2020;97:175-92. [PMID: 31791666 DOI: 10.1016/j.kint.2019.08.036] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
49 Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton) 2021;26:491-500. [PMID: 33550672 DOI: 10.1111/nep.13860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
50 Wang Y, Zhao L, Zhang J, Wu Y, Zhang R, Li H, Guo R, Han Q, Wang T, Li L, Wang S, Liu F. Implications of a Family History of Diabetes and Rapid eGFR Decline in Patients With Type 2 Diabetes and Biopsy-Proven Diabetic Kidney Disease. Front Endocrinol (Lausanne) 2019;10:855. [PMID: 31920969 DOI: 10.3389/fendo.2019.00855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Frodsham SG, Yu Z, Lyons AM, Agarwal A, Pezzolesi MH, Dong L, Srinivas TR, Ying J, Greene T, Raphael KL, Smith KR, Pezzolesi MG. The Familiality of Rapid Renal Decline in Diabetes. Diabetes 2019;68:420-9. [PMID: 30425064 DOI: 10.2337/db18-0838] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
52 Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, Gesualdo L, De Nicola L; Italian Diabetes Society and the Italian Society of Nephrology. Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". J Nephrol 2020;33:9-35. [PMID: 31576500 DOI: 10.1007/s40620-019-00650-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 23.0] [Reference Citation Analysis]
53 Costacou T, Orchard TJ. Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset. Diabetes Care 2018;41:426-33. [PMID: 28931542 DOI: 10.2337/dc17-1118] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 11.6] [Reference Citation Analysis]
54 Fukuda A, Minakawa A, Kikuchi M, Sato Y, Nagatomo M, Nakamura S, Mizoguchi T, Fukunaga N, Shibata H, Naik AS, Wiggins RC, Fujimoto S. Urinary podocyte mRNAs precede microalbuminuria as a progression risk marker in human type 2 diabetic nephropathy. Sci Rep 2020;10:18209. [PMID: 33097787 DOI: 10.1038/s41598-020-75320-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Colombo M, McGurnaghan SJ, Bell S, MacKenzie F, Patrick AW, Petrie JR, McKnight JA, MacRury S, Traynor J, Metcalfe W, McKeigue PM, Colhoun HM; Scottish Diabetes Research Network (SDRN) Type 1 Bioresource Investigators and the Scottish Renal Registry. Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia 2020;63:636-47. [PMID: 31807796 DOI: 10.1007/s00125-019-05052-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
56 Miyoshi H, Kameda H, Yamashita K, Nakamura A, Kurihara Y. Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes. J Diabetes Investig 2019;10:1510-7. [PMID: 31026373 DOI: 10.1111/jdi.13064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
57 Ramakrishnan R. Brain signalling systems: A target for treating type I diabetes mellitus. Brain Res Bull 2019;152:191-201. [PMID: 31325597 DOI: 10.1016/j.brainresbull.2019.07.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Furuichi K, Shimizu M, Yamanouchi M, Hoshino J, Sakai N, Iwata Y, Toyama T, Kitajima S, Hara A, Yuzawa Y, Kitamura H, Suzuki Y, Sato H, Uesugi N, Ueda Y, Nishi S, Nishino T, Samejima K, Kohagura K, Shibagaki Y, Makino H, Matsuo S, Ubara Y, Yokoyama H, Wada T. Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy. BMJ Open Diabetes Res Care 2020;8:e001157. [PMID: 32503809 DOI: 10.1136/bmjdrc-2019-001157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
59 Shirazian S, Grant C, Rambhujun V, Sharma R, Patel R, Islam S, Mattana J. A pilot trial to examine the association between circulating endothelial cell levels and vascular injury in patients with diabetes and chronic kidney disease. F1000Res 2016;5:292. [PMID: 27303625 DOI: 10.12688/f1000research.8005.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
60 Liu X, Du H, Sun Y, Shao L. Role of abnormal energy metabolism in the progression of chronic kidney disease and drug intervention. Ren Fail 2022;44:790-805. [PMID: 35535500 DOI: 10.1080/0886022X.2022.2072743] [Reference Citation Analysis]
61 Lee JH, Yang FJ, Tsai WY, Lee CT, Liu SY, Yang WS, Tung YC. Serum neutrophil gelatinase-associated lipocalin as a potential biomarker of diabetic kidney disease in patients with childhood-onset type 1 diabetes. J Formos Med Assoc 2021:S0929-6646(21)00302-8. [PMID: 34253435 DOI: 10.1016/j.jfma.2021.06.022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Ba Aqeel S, Ye M, Wysocki J, Sanchez A, Khattab A, Lores E, Rademaker A, Gao X, Bebu I, Nelson RG, Molitch M, Batlle D; Diabetes Control, Complications Trial (DCCT)/Epidemiology of Diabetes Interventions, Complications (EDIC) Study. Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. Physiol Rep 2019;7:e14242. [PMID: 31605461 DOI: 10.14814/phy2.14242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
63 Forbes JM, Fotheringham AK. Vascular complications in diabetes: old messages, new thoughts. Diabetologia 2017;60:2129-38. [DOI: 10.1007/s00125-017-4360-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
64 Popykhova EB, Ivanov AN, Stepanova TV, Lagutina DD, Savkina AA. Diabetic Nephropathy - possibilities of early laboratory diagnostics and course prediction (review of literature). Klin Lab Diagn 2021;66:593-602. [PMID: 34665945 DOI: 10.51620/0869-2084-2021-66-10-593-602] [Reference Citation Analysis]
65 Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ, Satake E, Simeone CA, Shah H, Qiu C, Looker HC, Fiorina P, Ware CF, Sun JK, Doria A, Kretzler M, Susztak K, Duffin KL, Nelson RG, Krolewski AS. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med 2019;25:805-13. [PMID: 31011203 DOI: 10.1038/s41591-019-0415-5] [Cited by in Crossref: 112] [Cited by in F6Publishing: 98] [Article Influence: 37.3] [Reference Citation Analysis]
66 Wang Y, Ding L, Wang R, Guo Y, Yang Z, Yu L, Wang L, Liang Y, Tang L. Circ_0004951 Promotes Pyroptosis of Renal Tubular Cells via the NLRP3 Inflammasome in Diabetic Kidney Disease. Front Med 2022;9:828240. [DOI: 10.3389/fmed.2022.828240] [Reference Citation Analysis]
67 Krolewski AS, Skupien J, Rossing P, Warram JH. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int 2017;91:1300-11. [PMID: 28366227 DOI: 10.1016/j.kint.2016.10.046] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 19.2] [Reference Citation Analysis]
68 Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig 2017;8:6-18. [PMID: 27181363 DOI: 10.1111/jdi.12533] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
69 Stratigou T, Vallianou N, Koutroumpi S, Vlassopoulou B, Apostolou T, Tsagarakis S, Ioannidis G. Progression of Albuminuria Among Patients with Type 1 Diabetes Mellitus: A Long Term Observational Follow-up Study. Exp Clin Endocrinol Diabetes 2021;129:276-82. [PMID: 30802917 DOI: 10.1055/a-0848-8076] [Reference Citation Analysis]
70 Srinivasan R, Gokulakrishnan K, Lourdusamy R, Nilavan E, Balaji N. Prevalence of rapid renal decliner phenotype in south India: A retrospective study. Diabetes Metab Syndr 2021;16:102334. [PMID: 34920201 DOI: 10.1016/j.dsx.2021.102334] [Reference Citation Analysis]
71 Melsom T, Nair V, Schei J, Mariani L, Stefansson VTN, Harder JL, Jenssen TG, Solbu MD, Norvik JV, Looker H, Knowler WC, Kretzler M, Nelson RG, Eriksen BO. Correlation Between Baseline GFR and Subsequent Change in GFR in Norwegian Adults Without Diabetes and in Pima Indians. Am J Kidney Dis 2019;73:777-85. [PMID: 30704883 DOI: 10.1053/j.ajkd.2018.11.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
72 Cefalu WT, Boulton AJ, Boulton AJ, Moses RG, LeRoith D, Greene EL, Hu FB, Bakris G, Wylie-Rosett J, Rosenstock J, Weinger K, Blonde L, de Groot M, Riddle MC, Henry R, Golden SH, Rich S, Reynolds L. Status of Diabetes Care: New Challenges, New Concepts, New Measures--Focusing on the Future! Diabetes Care 2015;38:1177-80. [PMID: 26312261 DOI: 10.2337/dc15-0875] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
73 Seo DH, Nam M, Jung M, Suh YJ, Ahn SH, Hong S, Kim SH. Serum Levels of Adipocyte Fatty Acid-Binding Protein Are Associated with Rapid Renal Function Decline in Patients with Type 2 Diabetes Mellitus and Preserved Renal Function. Diabetes Metab J 2020;44:875-86. [PMID: 32662255 DOI: 10.4093/dmj.2019.0221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
74 Bai X, Li X, Tian J, Xu L, Wan J, Liu Y. A new model of diabetic nephropathy in C57BL/6 mice challenged with advanced oxidation protein products. Free Radical Biology and Medicine 2018;118:71-84. [DOI: 10.1016/j.freeradbiomed.2018.02.020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
75 Ihara K, Skupien J, Kobayashi H, Md Dom ZI, Wilson JM, O'Neil K, Badger HS, Bowsman LM, Satake E, Breyer MD, Duffin KL, Krolewski AS. Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Diabetes Care 2020;43:2760-7. [PMID: 32887710 DOI: 10.2337/dc20-0630] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
76 Pugliese G, Penno G, Natali A, Barutta F, Di Paolo S, Reboldi G, Gesualdo L, De Nicola L; Italian Diabetes Society and the Italian Society of Nephrology. Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function". Nutr Metab Cardiovasc Dis 2019;29:1127-50. [PMID: 31586514 DOI: 10.1016/j.numecd.2019.07.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
77 Tagaya M, Kume S, Yasuda-yamahara M, Kuwagata S, Yamahara K, Takeda N, Tanaka Y, Chin-kanasaki M, Nakae Y, Yokoi H, Mukoyama M, Ishihara N, Nomura M, Araki S, Maegawa H. Inhibition of mitochondrial fission protects podocytes from albumin-induced cell damage in diabetic kidney disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2022. [DOI: 10.1016/j.bbadis.2022.166368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Lovrenčić MV, Biljak VR, Blaslov K, Božičević S, Duvnjak LS. Impact of creatinine methodology on glomerular filtration rate estimation in diabetes. World J Diabetes 2017; 8(5): 222-229 [PMID: 28572883 DOI: 10.4239/wjd.v8.i5.222] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
79 Griffin TP, Islam MN, Wall D, Ferguson J, Griffin DG, Griffin MD, O'Shea PM. Plasma dephosphorylated-uncarboxylated Matrix Gla-Protein (dp-ucMGP): reference intervals in Caucasian adults and diabetic kidney disease biomarker potential. Sci Rep 2019;9:18452. [PMID: 31804541 DOI: 10.1038/s41598-019-54762-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
80 Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 2018;14:291-312. [PMID: 29456246 DOI: 10.1038/nrneph.2018.9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 29.0] [Reference Citation Analysis]
81 Sircar M, Rosales IA, Selig MK, Xu D, Zsengeller ZK, Stillman IE, Libermann TA, Karumanchi SA, Thadhani RI. Complement 7 Is Up-Regulated in Human Early Diabetic Kidney Disease. Am J Pathol 2018;188:2147-54. [PMID: 30253844 DOI: 10.1016/j.ajpath.2018.06.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
82 Haraguchi R, Kohara Y, Matsubayashi K, Kitazawa R, Kitazawa S. New Insights into the Pathogenesis of Diabetic Nephropathy: Proximal Renal Tubules Are Primary Target of Oxidative Stress in Diabetic Kidney. Acta Histochem Cytochem 2020;53:21-31. [PMID: 32410750 DOI: 10.1267/ahc.20008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
83 Magagnotti C, Zerbini G, Fermo I, Carletti RM, Bonfanti R, Vallone F, Andolfo A. Identification of nephropathy predictors in urine from children with a recent diagnosis of type 1 diabetes. J Proteomics 2019;193:205-16. [PMID: 30366120 DOI: 10.1016/j.jprot.2018.10.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
84 Looker HC, Mauer M, Saulnier PJ, Harder JL, Nair V, Boustany-Kari CM, Guarnieri P, Hill J, Esplin CA, Kretzler M, Nelson RG, Najafian B. Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes. J Am Soc Nephrol 2019;30:1049-59. [PMID: 31152118 DOI: 10.1681/ASN.2018111166] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 10.5] [Reference Citation Analysis]
85 Skupien J, Warram JH, Smiles AM, Stanton RC, Krolewski AS. Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes. Diabetes Care 2016;39:2262-9. [PMID: 27647852 DOI: 10.2337/dc16-0950] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
86 Gültaş B, Özgül Ö, Cander S. Retrospective evaluation of microalbuminuria and GFR levels of diabetic patients taking DPP-4 Inhibitor, GLP-1 Analog, or SGLT-2 Inhibitor. Turkish Journal of Internal Medicine. [DOI: 10.46310/tjim.1072857] [Reference Citation Analysis]
87 Sourij H, Edlinger R, Prischl FC, Auinger M, Kaser S, Horn S, Paulweber B, Kautzky-willer A, Säemann M, Prager R, Clodi M, Schernthaner G, Mayer G, Oberbauer R, Rosenkranz AR. Diabetische Nierenerkrankung (Update 2019): Positionspapier der Österreichischen Diabetes Gesellschaft und der Österreichischen Gesellschaft für Nephrologie. Wien Klin Wochenschr 2019;131:151-63. [DOI: 10.1007/s00508-018-1425-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Scurt FG, Bose K, Canbay A, Mertens PR, Chatzikyrkou C. [Chronic kidney injury in patients with liver diseases - Reappraising pathophysiology and treatment options]. Z Gastroenterol 2021;59:560-79. [PMID: 33728618 DOI: 10.1055/a-1402-1502] [Reference Citation Analysis]
89 Lee K, Shin J, Park J, Hwang S, Jang HR, Huh W, Kwon GY, Kim YG, Oh HY, Lee JE, Kim DJ. First-year GFR slope and long-term renal outcome in IgA nephropathy. Eur J Clin Invest 2018;48:e12936. [PMID: 29660832 DOI: 10.1111/eci.12936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Critselis E, Vlahou A, Stel VS, Morton RL. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrology Dialysis Transplantation 2018;33:441-9. [DOI: 10.1093/ndt/gfx068] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
91 Chang J, Yan J, Li X, Liu N, Zheng R, Zhong Y. Update on the Mechanisms of Tubular Cell Injury in Diabetic Kidney Disease. Front Med (Lausanne) 2021;8:661076. [PMID: 33859992 DOI: 10.3389/fmed.2021.661076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Chen Y, Lee K, Ni Z, He JC. Diabetic Kidney Disease: Challenges, Advances, and Opportunities. Kidney Dis (Basel) 2020;6:215-25. [PMID: 32903946 DOI: 10.1159/000506634] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
93 Nowak N. Protective factors as biomarkers and targets for prevention and treatment of diabetic nephropathy: From current human evidence to future possibilities. J Diabetes Investig 2020;11:1085-96. [PMID: 32196975 DOI: 10.1111/jdi.13257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
94 Li LP, Tan H, Thacker JM, Li W, Zhou Y, Kohn O, Sprague SM, Prasad PV. Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging. Kidney Int Rep 2017;2:36-43. [PMID: 28868513 DOI: 10.1016/j.ekir.2016.09.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
95 Barutta F, Bellini S, Canepa S, Durazzo M, Gruden G. Novel biomarkers of diabetic kidney disease: current status and potential clinical application. Acta Diabetol 2021;58:819-30. [PMID: 33528734 DOI: 10.1007/s00592-020-01656-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
96 Ishizuka T, Tokuyama Y, Horie A, Hatanaka Y, Sato S, Kanatsuka A. Relationship between kidney function decline and initial risk factors for the progression of diabetic kidney disease: a retrospective analysis of 91 Japanese patients with type 2 diabetes. Diabetol Int 2016;7:432-9. [PMID: 30603296 DOI: 10.1007/s13340-016-0270-2] [Reference Citation Analysis]
97 Cao Q, Chen XM, Huang C, Pollock CA. MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update. FASEB Bioadv 2019;1:375-88. [PMID: 32123840 DOI: 10.1096/fba.2018-00064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
98 Boettcher C, Utsch B, Galler A, Grasemann C, Borkenstein M, Denzer C, Heidtmann B, Tittel SR, Holl RW; DPV initiative. Estimated Glomerular Filtration Rates Calculated by New and Old Equations in Children and Adolescents With Type 1 Diabetes-What to Do With the Results? Front Endocrinol (Lausanne) 2020;11:52. [PMID: 32153499 DOI: 10.3389/fendo.2020.00052] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
99 Żyłka A, Dumnicka P, Kuśnierz-Cabala B, Gala-Błądzińska A, Ceranowicz P, Kucharz J, Ząbek-Adamska A, Maziarz B, Drożdż R, Kuźniewski M. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators Inflamm 2018;2018:7659243. [PMID: 30158836 DOI: 10.1155/2018/7659243] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
100 Li M, Pezzolesi MG. Advances in understanding the genetic basis of diabetic kidney disease. Acta Diabetol 2018;55:1093-104. [PMID: 30083980 DOI: 10.1007/s00592-018-1193-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
101 Pini A, Grange C, Veglia E, Argenziano M, Cavalli R, Guasti D, Calosi L, Ghè C, Solarino R, Thurmond RL, Camussi G, Chazot PL, Rosa AC. Histamine H4 receptor antagonism prevents the progression of diabetic nephropathy in male DBA2/J mice. Pharmacol Res 2018;128:18-28. [PMID: 29309903 DOI: 10.1016/j.phrs.2018.01.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
102 Garofolo M, Russo E, Miccoli R, Lucchesi D, Giusti L, Sancho-Bornez V, Daniele G, Del Prato S, Penno G. Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality. J Diabetes Complications 2018;32:550-7. [PMID: 29705091 DOI: 10.1016/j.jdiacomp.2018.03.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
103 Squitti R, Negrouk V, Perera M, Llabre MM, Ricordi C, Rongioletti MCA, Mendez AJ. Serum copper profile in patients with type 1 diabetes in comparison to other metals. J Trace Elem Med Biol 2019;56:156-61. [PMID: 31472477 DOI: 10.1016/j.jtemb.2019.08.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 Abe M, Okada K, Maruyama N, Takashima H, Oikawa O, Soma M. Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. J Diabetes Res 2016;2016:5374746. [PMID: 26839894 DOI: 10.1155/2016/5374746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]